The company previously announced that it had filed an investigational new drug application with the FDA for an oral formulation of picoplatin in February 2007.
The phase I trial is comparing the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously in approximately 18 patients with advanced solid tumor malignancies. The trial is being conducted at clinical sites in the US and is expected to take six months to complete.